Ethic Inc. Decreases Holdings in DexCom, Inc. $DXCM

Ethic Inc. decreased its stake in DexCom, Inc. (NASDAQ:DXCM) by 38.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,295 shares of the medical device company’s stock after selling 18,910 shares during the quarter. Ethic Inc.’s holdings in DexCom were worth $2,039,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Andra AP fonden purchased a new position in DexCom in the 2nd quarter valued at about $26,000. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom during the second quarter valued at approximately $26,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the second quarter valued at approximately $45,000. Anderson Financial Strategies LLC purchased a new position in shares of DexCom in the first quarter valued at approximately $37,000. Finally, Sound Income Strategies LLC boosted its stake in shares of DexCom by 83.8% in the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after acquiring an additional 285 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 1.0%

Shares of NASDAQ DXCM opened at $66.37 on Friday. The company has a market capitalization of $25.89 billion, a P/E ratio of 36.87, a P/E/G ratio of 1.43 and a beta of 1.48. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The company has a 50 day simple moving average of $63.81 and a 200-day simple moving average of $72.73. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $93.25.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.45 earnings per share. On average, equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other DexCom news, COO Jacob Steven Leach purchased 18,200 shares of the stock in a transaction dated Monday, November 10th. The stock was acquired at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the acquisition, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. This trade represents a 5.81% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the sale, the director directly owned 27,031 shares of the company’s stock, valued at $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,866 shares of company stock valued at $448,177 in the last quarter. Insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on DXCM shares. Morgan Stanley raised DexCom from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $63.00 to $75.00 in a research note on Tuesday, December 2nd. The Goldman Sachs Group reduced their target price on shares of DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. JPMorgan Chase & Co. lowered their price target on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Finally, Stifel Nicolaus began coverage on shares of DexCom in a report on Tuesday, October 21st. They issued a “buy” rating and a $85.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.61.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.